SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

• César Serrano ^[6] ; Rosa Álvarez ^[1] ; Juan Antonio Carrasco ^[7] ; Gloria Marquina ^[2] ; Jerónimo Martínez-García ^[8] ; Virginia Martínez-Marín ^[3] ; María Ángeles Sala ^[9] ; Ana Sebio ^[4] ; Isabel Sevilla ^[10] ; Javier Martín-Broto ^[5]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  5. [5] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  6. [6] Grupo de Investigación Traslacional del Sarcoma, Instituto de Oncología Vall d’Hebron (VHIO), Hospital Universitario Vall d’Hebron, Campus del Hospital Vall d’Hebron Barcelona, C/Natzaret, 115-117, 08035, Barcelona, España
  7. [7] Hospital Álvaro Cunqueiro–Complejo Hospitalario Universitario de Vigo, Pontevedra, España
  8. [8] Hospital Universitario Virgen de la Arrixaca, Murcia, España
  9. [9] Hospital Universitario Basurto, Bilbao, España
  10. [10] Hospitales Universitarios Regional y Virgen de la Victoria, Málaga, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2707-2717
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.